A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics

BackgroundA recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated.ObjectiveThe current study compared the risks of AKI and known causes of AKI associated with a broad range of atypical and typical antipsychotics.MethodThis retrospective cohort analysis used January 2007–June 2013 US nationwide Humana claims data to define episodes of antipsychotic drug therapy for patients with schizophrenia and bipolar disorder. Study drugs were aripiprazole, fluphenazine, haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone. Study outcomes were hospitalizations with AKI, and known causes of AKI, i.e., hypotension, acute urinary retention, neuroleptic malignant syndrome/rhabdomyolysis, and pneumonia. AKI was the primary outcome of the study. Cox regressions using haloperidol as the baseline comparator were used to estimate the impact of alternative antipsychotics on the risks of study adverse events following the initiation of treatment. The Cox models controlled for treatment history, comorbidities, and concomitant drug use in the prior 6 months. They also controlled for patient demographics and dose of current treatment.ResultsThe overall incidence of AKI was 25.0 per 1000 person-years. According to our multivariate regression results, the risk of AKI was significantly increased in patients taking olanzapine [hazard ratio (HR) 1.344, 95% confidence interval (CI) 1.057–1.708], quetiapine (HR 1.350, 95% CI 1.082–1.685), and ziprasidone (HR 1.338, 95% CI 1.035–1.729) relative to haloperidol. Aripiprazole (HR 1.152, 95% CI 0.908–1.462) and risperidone (HR 1.147, 95% CI 0.923–1.426) had insignificantly higher risks of AKI compared with haloperidol, whereas fluphenazine (HR 0.729, 95% CI 0.483–1.102) had an insignificantly lower risk of AKI. When compared between drug classes, atypical antipsychotics had a significantly higher risk of AKI (HR 1.313, 95% CI 1.083–1.591) than typical antipsychotics.ConclusionsAntipsychotics are associated with differential AKI risks, with several atypical antipsychotics having higher risks than haloperidol. However, the overall incidence of AKI was moderate, and AKI risk should only raise concern for clinicians with elderly patients or patients who are vulnerable to kidney disease.

[1]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[2]  Michael Schemper,et al.  Comparing Cox and parametric models in clinical studies , 2003, Statistics in medicine.

[3]  P. Lapuerta,et al.  Non-adherence to antipsychotic medication regimens: Associations with resource use and costs , 2004, British Journal of Psychiatry.

[4]  P. Weiden,et al.  Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. , 2004, Psychiatric services.

[5]  A. Mortimer.  Atypical Antipsychotics as First-Line Treatments for Schizophrenia , 2004 .

[6]  J. Satagopan,et al.  A note on competing risks in survival data analysis , 2004, British Journal of Cancer.

[7]  A. Cameron,et al.  Microeconometrics: Methods and Applications , 2005 .

[8]  J. Newcomer,et al.  The Metabolic Effects of Antipsychotic Medications , 2006, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[9]  H. Nasrallah,et al.  Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[10]  Sushrut S Waikar,et al.  Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. , 2006, Journal of the American Society of Nephrology : JASN.

[11]  S. Gentile.  Atypical Antipsychotics for the Treatment of Bipolar Disorder , 2007, CNS drugs.

[12]  J. Mccombs,et al.  The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  Paul J Rathouz,et al.  Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. , 2008, Journal of health economics.

[14]  Bradley N Gaynes,et al.  Prescription refill records as a screening tool to identify antidepressant non‐adherence , 2010, Pharmacoepidemiology and drug safety.

[15]  R. Baldessarini,et al.  International consensus study of antipsychotic dosing. , 2010, The American journal of psychiatry.

[16]  Chih-lin Chiang,et al.  Micturition difficulty associated with aripiprazole: report of 2 cases. , 2011, Journal of clinical psychopharmacology.

[17]  Jodi M. Gonzalez,et al.  Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder , 2011, Patient preference and adherence.

[18]  James J. Gugger,et al.  Antipsychotic Pharmacotherapy and Orthostatic Hypotension , 2011, CNS drugs.

[19]  O. Dursun,et al.  Nephrotoxic Effects of Chronically Administered Olanzapine and Risperidone in Male Rats , 2012 .

[20]  Brian Sauer,et al.  The incident user design in comparative effectiveness research , 2013, Pharmacoepidemiology and drug safety.

[21]  Carmine Zoccali,et al.  When do we need competing risks methods for survival analysis in nephrology? , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  J. Lave,et al.  The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries. , 2013, Psychiatric services.

[23]  J. Donohue,et al.  Diffusion of antipsychotics in the US And French markets, 1998-2008. , 2013, Psychiatric services.

[24]  Haiden A Huskamp,et al.  How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. , 2013, Psychiatric services.

[25]  Youming Peng,et al.  Dibenzodiazepine Derivative Quetiapine- and Olanzapine-Induced Chronic Interstitial Nephritis , 2013, Renal failure.

[26]  E. Berndt,et al.  Changes in physician antipsychotic prescribing preferences, 2002-2007. , 2014, Psychiatric services.

[27]  James Carpenter,et al.  Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputation , 2014, Statistics in medicine.

[28]  S. Bowry,et al.  An inadvertent but explicable error in calculating number needed to treat for reporting survival data. , 2014, Journal of the American Society of Nephrology : JASN.

[29]  A. Garg,et al.  Atypical Antipsychotic Drugs and the Risk for Acute Kidney Injury and Other Adverse Outcomes in Older Adults , 2014, Annals of Internal Medicine.

[30]  B. Colaco,et al.  Clozapine induced tubulointerstitial nephritis in a patient with paranoid schizophrenia , 2014, BMJ Case Reports.

[31]  M. Hasnain,et al.  QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review , 2014, CNS Drugs.

[32]  M. Perazella,et al.  Acute kidney injury and mortality in the elderly: add atypical antipsychotics to the list. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  M. Pompili,et al.  Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis , 2015, Drugs in R&D.

[34]  G. Trifirò,et al.  Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta‐analysis of observational studies , 2015, Pharmacoepidemiology and drug safety.

[35]  Yawen Jiang,et al.  Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization , 2015, Pharmacotherapy.

[36]  Yawen Jiang,et al.  Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment. , 2015, Journal of managed care & specialty pharmacy.

[37]  D. Seitz,et al.  New use of antipsychotics associated with a small increased risk of acute kidney injury in older adults with mental disorders , 2015, Evidence-Based Mental Health.

[38]  E. Muser,et al.  Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States , 2016, Journal of clinical psychopharmacology.